Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States of America.
Department of Public Health Sciences, Biostatistics Section, University of Virginia, Charlottesville, VA, United States of America.
PLoS One. 2018 Oct 5;13(10):e0204352. doi: 10.1371/journal.pone.0204352. eCollection 2018.
We previously reported association of SCARB1 SNP rs10846744 with common carotid IMT (cIMT) and cardiovascular disease (CVD) events. Since rs10846744 has been reported in association with Lp-PLA2 mass and activity, we hypothesized that inflammatory pathways might mediate the association of rs10846744 with atherosclerosis.
We first examined association of rs10846744 in CVD in multiple large-scale consortium-based genome-wide association studies. We further examined 27 parameters of interest, including Lp-PLA2 mass and activity, inflammatory markers, and plasma phospholipid fatty acids, and fatty acid ratios in participants from the Multi-Ethnic Study of Atherosclerosis (MESA), as potential mediators in the pathway linking rs10846744 with cIMT and incident CVD. Finally, we examined the association of rs10846744 with Lp-PLA2 activity, cardiovascular outcomes, and interaction with the Lp-PLA2 inhibitor, darapladib, in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) and Stabilization of Plaque using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) studies.
SCARB1 rs10846744 was associated with coronary artery disease events in CARDIoGRAMplusC4D (odds ratio 1.05; 95% CI [1.02, 1.07]; P = 1.4x10-4). In combined analysis across race/ethnic groups in MESA, rs10846744 was associated with Lp-PLA2 mass (P = 0.04) and activity (P = 0.001), homocysteine (P = 0.03), LDL particle number (P = 0.01), docosahexaenoic acid [DHA] (P = 0.01), docosapentaenoic acid [DPA] (P = 0.04), DPA/ eicosapentaenoic acid [EPA] ratio (P = 0.002), and DHA/EPA ratio (P = 0.008). Lp-PLA2 activity was identified as a mediator of rs10846744 with cIMT in a basic model (P = 8x10-5), but not after adjustment for CVD risk factors. There was no interaction or modifier effect of the Lp-PLA2 inhibitor darapladib assignment on the relationship between rs10846744 and major CVD events in either STABILITY or SOLID-TIMI 52.
SCARB1 rs10846744 is significantly associated with Lp-PLA2 activity, atherosclerosis, and CVD events, but Lp-PLA2 activity is not a mediator in the association of rs10846744 with cIMT in MESA.
我们之前报道过 SCARB1 SNP rs10846744 与颈总动脉 IMT(cIMT)和心血管疾病(CVD)事件有关。由于 rs10846744 与 Lp-PLA2 质量和活性有关,我们假设炎症途径可能介导 rs10846744 与动脉粥样硬化的关联。
我们首先在多个大规模基于联盟的全基因组关联研究中检验了 rs10846744 在 CVD 中的关联。我们进一步研究了 27 个感兴趣的参数,包括 Lp-PLA2 质量和活性、炎症标志物、载脂蛋白磷脂脂肪酸和载脂蛋白脂肪酸比,这些参数在动脉粥样硬化多民族研究(MESA)中的参与者中作为潜在的中介物,以连接 rs10846744 与 cIMT 和新发 CVD。最后,我们在启动达拉普利治疗稳定动脉粥样硬化斑块研究(STABILITY)和达拉普利溶栓治疗心肌梗死 52 研究(SOLID-TIMI 52)中,检验了 rs10846744 与 Lp-PLA2 活性、心血管结局以及与 Lp-PLA2 抑制剂达拉普利的相互作用。
SCARB1 rs10846744 与 CARDIoGRAMplusC4D 中的冠状动脉疾病事件有关(优势比 1.05;95%CI[1.02,1.07];P=1.4x10-4)。在 MESA 中跨种族/族裔群体的综合分析中,rs10846744 与 Lp-PLA2 质量(P=0.04)和活性(P=0.001)、同型半胱氨酸(P=0.03)、LDL 颗粒数(P=0.01)、二十二碳六烯酸[DHA](P=0.01)、二十二碳五烯酸[DPA](P=0.04)、DPA/二十碳五烯酸[EPA] 比值(P=0.002)和 DHA/EPA 比值(P=0.008)有关。Lp-PLA2 活性在基本模型中被确定为 rs10846744 与 cIMT 之间的中介物(P=8x10-5),但在调整 CVD 危险因素后则不是。在 STABILITY 或 SOLID-TIMI 52 中,Lp-PLA2 抑制剂达拉普利的分配与 rs10846744 与主要 CVD 事件之间的关系均无相互作用或修饰效应。
SCARB1 rs10846744 与 Lp-PLA2 活性、动脉粥样硬化和 CVD 事件显著相关,但 Lp-PLA2 活性不是 MESA 中 rs10846744 与 cIMT 关联的中介物。